Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Myeloid Blood Cancer Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
The rising prevalence of myeloid blood cancer, along with the growing elderly population worldwide are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the development of innovative combination therapies and the increasing incidence of myeloid blood cancer among children on a global level.
Myeloid Blood Cancer Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Prevalence of Myeloid Blood Cancer
- Growing Elderly Population Worldwide
Challenges
- Expensive Myeloid Blood Cancer Treatment Therapies
- Strict Regulation on Drugs in Some Regions
Myeloid Blood Cancer Treatment Segmentation
The myeloid blood cancer treatment market is segmented on the basis of treatment type into chemotherapy, immunotherapy, radiotherapy, targeted therapy, stem cell therapy, and others, out of which, the targeted therapy segment is anticipated to grab the largest share by the end of 2021 on account of higher positive diagnosis rates and better efficiency of targeted therapy than chemotherapy. Moreover, immunotherapy is also widely being used for the treatment of myeloid blood cancer, which is also projected to contribute to the growth of the market during the forecast period.
On the basis of end-user, the specialty hospitals segment in the global myeloid blood cancer treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that myeloid blood cancer is a relatively rare occurrence and as a result, a considerable portion of the population with this cancer on a global level tend to choose healthcare facilities specializing in its treatment.
Our in-depth analysis of the global market includes the following segments
|
By Treatment Type |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMyeloid Blood Cancer Treatment Industry - Regional Synopsis
APAC Market Statistics
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. Asia Pacific industry is poised to account for largest revenue share by 2037, owing to increasing awareness about myeloid blood cancer and need to develop innovative cancer treatment solutions in the region.
North America Market Analysis
Furthermore, in 2021, the myeloid blood cancer treatment market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in myeloid blood cancer research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also has a high prevalence of myeloid blood cancer, which is also expected to contribute to the market growth in the region.
Europe Market Analysis
Alternatively, the market in Europe is also anticipated to occupy a significant share in the myeloid blood cancer treatment market on account of increase in expenditure on research and development and a high prevalence of myeloid blood cancer in the region.
Companies Dominating the Myeloid Blood Cancer Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb
- F. Hoffmann-La Roche AG
- Teva Pharmaceuticals
- Sanofi
- AbbVie
- Gilead Sciences
- Novartis AG
- Amgen, Inc.
Author Credits: Radhika Pawar
- Report ID: 3023
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
